Biocon, JDRF in deal for insulin tregopil study

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) and JDRF (New York, N.Y.) partnered to conduct a two-part, open-label Phase I study of insulin tregopil to treat Type I diabetes. The trial's first part will determine the optimal dosing and regimen of the oral conjugated insulin analog. The second part will evaluate pharmacokinetics and pharmacodynamics of the candidate plus NovoLog insulin aspart during real-world scenarios, including with meals. The European study will enroll about 70 patients. The partnership is part of JDRF's Industry Discovery and Development Partnership (IDDP) program. The partners declined to disclose financial terms.

Biocon has submitted a clinical trial application for a Phase II/III study in India of insulin tregopil to treat Type II diabetes...